These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 25313322)

  • 1. Discovery of 2-Pyridylpyrimidines as the First Orally Bioavailable GPR39 Agonists.
    Peukert S; Hughes R; Nunez J; He G; Yan Z; Jain R; Llamas L; Luchansky S; Carlson A; Liang G; Kunjathoor V; Pietropaolo M; Shapiro J; Castellana A; Wu X; Bose A
    ACS Med Chem Lett; 2014 Oct; 5(10):1114-8. PubMed ID: 25313322
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel Zn2+ Modulated GPR39 Receptor Agonists Do Not Drive Acute Insulin Secretion in Rodents.
    Fjellström O; Larsson N; Yasuda S; Tsuchida T; Oguma T; Marley A; Wennberg-Huldt C; Hovdal D; Fukuda H; Yoneyama Y; Sasaki K; Johansson A; Lundqvist S; Brengdahl J; Isaacs RJ; Brown D; Geschwindner S; Benthem L; Priest C; Turnbull A
    PLoS One; 2015; 10(12):e0145849. PubMed ID: 26720709
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Isolation of Zn2+ as an endogenous agonist of GPR39 from fetal bovine serum.
    Yasuda S; Miyazaki T; Munechika K; Yamashita M; Ikeda Y; Kamizono A
    J Recept Signal Transduct Res; 2007; 27(4):235-46. PubMed ID: 17885920
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Disruption of G protein-coupled receptor 39 impairs insulin secretion in vivo.
    Tremblay F; Richard AM; Will S; Syed J; Stedman N; Perreault M; Gimeno RE
    Endocrinology; 2009 Jun; 150(6):2586-95. PubMed ID: 19213841
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Model-Based Discovery of Synthetic Agonists for the Zn
    Frimurer TM; Mende F; Graae AS; Engelstoft MS; Egerod KL; Nygaard R; Gerlach LO; Hansen JB; Schwartz TW; Holst B
    J Med Chem; 2017 Feb; 60(3):886-898. PubMed ID: 28045522
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Zinc-Sensing Receptor GPR39 in Physiology and as a Pharmacological Target.
    Laitakari A; Liu L; Frimurer TM; Holst B
    Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33918078
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-lasting antidepressant-like activity of the GPR39 zinc receptor agonist TC-G 1008.
    Starowicz G; Jarosz M; Frąckiewicz E; Grzechnik N; Ostachowicz B; Nowak G; Mlyniec K
    J Affect Disord; 2019 Feb; 245():325-334. PubMed ID: 30419533
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chemical Probe Identification Platform for Orphan GPCRs Using Focused Compound Screening: GPR39 as a Case Example.
    Boehm M; Hepworth D; Loria PM; Norquay LD; Filipski KJ; Chin JE; Cameron KO; Brenner M; Bonnette P; Cabral S; Conn E; Ebner DC; Gautreau D; Hadcock J; Lee EC; Mathiowetz AM; Morin M; Rogers L; Smith A; VanVolkenburg M; Carpino PA
    ACS Med Chem Lett; 2013 Nov; 4(11):1079-84. PubMed ID: 24900608
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of novel pyrrole-based scaffold as potent and orally bioavailable free fatty acid receptor 1 agonists for the treatment of type 2 diabetes.
    Li Z; Pan M; Su X; Dai Y; Fu M; Cai X; Shi W; Huang W; Qian H
    Bioorg Med Chem; 2016 May; 24(9):1981-7. PubMed ID: 27020683
    [TBL] [Abstract][Full Text] [Related]  

  • 10. GI functions of GPR39: novel biology.
    Depoortere I
    Curr Opin Pharmacol; 2012 Dec; 12(6):647-52. PubMed ID: 22884904
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of Potent and Orally Bioavailable Dihydropyrazole GPR40 Agonists.
    Shi J; Gu Z; Jurica EA; Wu X; Haque LE; Williams KN; Hernandez AS; Hong Z; Gao Q; Dabros M; Davulcu AH; Mathur A; Rampulla RA; Gupta AK; Jayaram R; Apedo A; Moore DB; Liu H; Kunselman LK; Brady EJ; Wilkes JJ; Zinker BA; Cai H; Shu YZ; Sun Q; Dierks EA; Foster KA; Xu C; Wang T; Panemangalore R; Cvijic ME; Xie C; Cao GG; Zhou M; Krupinski J; Whaley JM; Robl JA; Ewing WR; Ellsworth BA
    J Med Chem; 2018 Feb; 61(3):681-694. PubMed ID: 29316397
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Up-regulation of the GPR39 Zn2+-sensing receptor and CREB/BDNF/TrkB pathway after chronic but not acute antidepressant treatment in the frontal cortex of zinc-deficient mice.
    Młyniec K; Nowak G
    Pharmacol Rep; 2015 Dec; 67(6):1135-40. PubMed ID: 26481532
    [TBL] [Abstract][Full Text] [Related]  

  • 13. GPR39 receptors and actions of trace metals on pancreatic beta cell function and glucose homoeostasis.
    Moran BM; Abdel-Wahab YH; Vasu S; Flatt PR; McKillop AM
    Acta Diabetol; 2016 Apr; 53(2):279-93. PubMed ID: 26112416
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potential antidepressant-like properties of the TC G-1008, a GPR39 (zinc receptor) agonist.
    Młyniec K; Starowicz G; Gaweł M; Frąckiewicz E; Nowak G
    J Affect Disord; 2016 Sep; 201():179-84. PubMed ID: 27235821
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A G-protein coupled receptor 39 agonist stimulates proliferation of keratinocytes via an ERK-dependent pathway.
    Satianrapapong W; Pongkorpsakol P; Muanprasat C
    Biomed Pharmacother; 2020 Jul; 127():110160. PubMed ID: 32371316
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of DS-1558: A Potent and Orally Bioavailable GPR40 Agonist.
    Takano R; Yoshida M; Inoue M; Honda T; Nakashima R; Matsumoto K; Yano T; Ogata T; Watanabe N; Hirouchi M; Yoneyama T; Ito S; Toda N
    ACS Med Chem Lett; 2015 Mar; 6(3):266-70. PubMed ID: 25815144
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of PF-5190457, a Potent, Selective, and Orally Bioavailable Ghrelin Receptor Inverse Agonist Clinical Candidate.
    Bhattacharya SK; Andrews K; Beveridge R; Cameron KO; Chen C; Dunn M; Fernando D; Gao H; Hepworth D; Jackson VM; Khot V; Kong J; Kosa RE; Lapham K; Loria PM; Londregan AT; McClure KF; Orr ST; Patel J; Rose C; Saenz J; Stock IA; Storer G; VanVolkenburg M; Vrieze D; Wang G; Xiao J; Zhang Y
    ACS Med Chem Lett; 2014 May; 5(5):474-9. PubMed ID: 24900864
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structural basis for GLP-1 receptor activation by LY3502970, an orally active nonpeptide agonist.
    Kawai T; Sun B; Yoshino H; Feng D; Suzuki Y; Fukazawa M; Nagao S; Wainscott DB; Showalter AD; Droz BA; Kobilka TS; Coghlan MP; Willard FS; Kawabe Y; Kobilka BK; Sloop KW
    Proc Natl Acad Sci U S A; 2020 Nov; 117(47):29959-29967. PubMed ID: 33177239
    [TBL] [Abstract][Full Text] [Related]  

  • 19. G protein-coupled receptor 39 deficiency is associated with pancreatic islet dysfunction.
    Holst B; Egerod KL; Jin C; Petersen PS; Østergaard MV; Hald J; Sprinkel AM; Størling J; Mandrup-Poulsen T; Holst JJ; Thams P; Orskov C; Wierup N; Sundler F; Madsen OD; Schwartz TW
    Endocrinology; 2009 Jun; 150(6):2577-85. PubMed ID: 19213833
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of TAK-875: A Potent, Selective, and Orally Bioavailable GPR40 Agonist.
    Negoro N; Sasaki S; Mikami S; Ito M; Suzuki M; Tsujihata Y; Ito R; Harada A; Takeuchi K; Suzuki N; Miyazaki J; Santou T; Odani T; Kanzaki N; Funami M; Tanaka T; Kogame A; Matsunaga S; Yasuma T; Momose Y
    ACS Med Chem Lett; 2010 Sep; 1(6):290-4. PubMed ID: 24900210
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.